Methylation analysis for soft tissue lesions and rapid classification

Submission date	Recruitment status Recruiting	[X] Prospectively registered		
14/05/2025		☐ Protocol		
Registration date	Overall study status Ongoing Condition category	Statistical analysis plan		
21/05/2025		Results		
Last Edited		Individual participant data		
20/06/2025	Cancer	[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

To find out the cause, soft tissue lumps are often investigated with a biopsy or removal of the lump and examination of the cells under a microscope. However, in some cases, diagnosis is challenging based upon the appearance of the cells alone. In these cases, DNA testing to find out the genetic make-up of the lump may be requested by doctors. However, currently, the results of DNA tests can take weeks or months to be available, delaying diagnosis. In this study, we wish to test the accuracy and reliability of a novel genetic (DNA) test which may diagnose and classify soft tissue lumps more rapidly than conventional NHS practice. If this is successful, this could reduce the delays sometimes experienced by patients and hopefully improve treatment and outcomes.

Who can participate?

Adults with a soft tissue lump requiring either biopsy or surgical excision will be invited to take part.

What does the study involve?

In this study, we wish to collect a sample of tissue from participants undergoing biopsy or surgery of a soft tissue lump, for additional DNA analysis. Participants will not need to attend any additional appointments or visits with the research team.

What are the possible benefits and risks of participating?

There will be no direct benefit to participants from taking part, but the information we get from this study may help diagnose soft tissue lumps more quickly and easily in future. This may help us to identify treatments for patients and improve outcomes for patients going forward. At present, the analysis performed as part of this study is for research use only, and as such, cannot be used by the clinical team or benefit clinical care. As no separate, standalone, additional interventions or procedures are planned in this study, the risks of taking part are minimal. For participants having tissue samples taken during a biopsy procedure, they may feel more discomfort or pain during the procedure as two additional passes will need to be taken by the radiologist.

Where is the study run from?

This research is being managed by the University of Nottingham.

When is the study starting and how long is it expected to run for?

This study is expected to start recruitment in July 2025, and run until June 2027.

Who is funding the study?

This research is being funded by the National Institute of Health and Care Research Biomedical Research Centre, Nottingham.

Who is the main contact?

Name: Mr. Christopher Deacon

Email: christopher.deacon@nottingham.ac.uk

Contact information

Type(s)

Public

Contact name

Mr Christopher Deacon

ORCID ID

https://orcid.org/0000-0001-6975-8010

Contact details

Department of Academic Orthopaedics C floor, West Block Queen's Medical Centre Derby Road Nottingham United Kingdom NG7 2UH +44 115 82 31113 christopher.deacon@nottingham.ac.uk

Type(s)

Scientific, Principal investigator

Contact name

Prof Matthew Loose

ORCID ID

https://orcid.org/0000-0002-5264-0929

Contact details

Room D132 Queens Medical Centre Queen's Medical Centre Derby Road Nottingham United Kingdom

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

353961

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

25015

Study information

Scientific Title

Nanopore-based methylome classification and next-day comprehensive tumour profiling for ultra-rapid tumour diagnostics in soft-tissue sarcomas

Acronym

MASTERClass

Study objectives

The main purpose of this study is to demonstrate the feasibility of a novel nanopore-based adaptive targeting protocol for methylation-based sarcoma classification, in parallel with long-read SNV, fusion and CNV analysis. Primary endpoint comparison will be against current standard-of-care histopathological assessment, as per standard NHS clinical practice. The hypothesis of this study is that methylation analysis provides accurate diagnosis and classification comparable to current standard-of-care techniques.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 12/05/2025, Nottingham 2 REC (Health Research Authority, 2 Redman Place, Stratford, E20 1JQ, United Kingdom; +44 207 104 8009; nottingham2.rec@hra.nhs.uk), ref: 25/EM/0096

Study design

Single-centre prospective observational study

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Diagnosis of sarcoma in adults

Interventions

Participants will have one tissue sample collected, either from an additional core biopsy taken at the time of diagnosis, or via sampling of the surgically resected lesion at the time of its excision.

Tumour DNA methylome analysis will be performed in parallel with long-read SNV, fusion and CNV analysis, using the PromethION platform (Oxford Nanopore Technologies, Oxford, UK).

Intervention Type

Genetic

Primary outcome(s)

Percentage of sarcoma diagnoses correctly predicted by methylation-based classification, at 12 months post-biopsy or surgery

Key secondary outcome(s))

Percentage of sarcomas in which known pathognomonic molecular features are correctly identified by nanopore long-read sequencing, at 12 months post-biopsy or surgery

Completion date

30/06/2027

Eligibility

Key inclusion criteria

- 1. Considered to have sarcomatous soft-tissue lesion requiring biopsy or surgical excision
- 2. A good comprehension of the English language
- 3. Age ≥18 years old
- 4. Ability to give informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Patients in which the usual care team believe the lesion to have low risk of malignancy (i.e., most likely a benign lesion based on clinical history, examination and investigation findings)

Date of first enrolment

20/06/2025

Date of final enrolment

30/06/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Nottingham University Hospitals NHS Trust - Queen's Medical Centre Campus

Nottingham University Hospital Derby Road Nottingham United Kingdom NG7 2UH

Study participating centre

Nottingham University Hospitals NHS Trust - City Campus

Nottingham City Hospital Hucknall Road Nottingham United Kingdom NG5 1PB

Study participating centre University of Nottingham

University Park Nottingham United Kingdom NG7 2RD

Sponsor information

Organisation

University of Nottingham

ROR

https://ror.org/01ee9ar58

Funder(s)

Funder type

Government

Funder Name

NIHR BRC Nottingham, MSIR theme

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes